Home  »  Companies   »  Epizyme Inc. (EPZM) Reveals an Earnings Mystery...

Epizyme Inc. (EPZM) Reveals an Earnings Mystery

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

Epizyme Inc. (NASDAQ:EPZM) went up by 7.11% from its latest closing price compared to the recent 1-year high of $12.69. The company’s stock price has collected -10.07% of loss in the last five trading sessions. Press Release reported 15 hours ago that Epizyme Provides Business Highlights, Preliminary Fourth Quarter and Full Year 2021 Financials and Clinical Trial Updates

Is It Worth Investing in Epizyme Inc. (NASDAQ :EPZM) Right Now?

Plus, the 36-month beta value for EPZM is at 1.00. Opinions of the stock are interesting as 4 analysts out of 5 who provided ratings for Epizyme Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


The average price from analysts is $10.40, which is $7.99 above the current price. EPZM currently public float of 84.54M and currently shorts hold a 9.54% ratio of that float. Today, the average trading volume of EPZM was 1.58M shares.

EPZM’s Market Performance

EPZM stocks went down by -10.07% for the week, with a monthly drop of -16.90% and a quarterly performance of -51.90%, while its annual performance rate touched -80.05%. The volatility ratio for the week stands at 8.64% while the volatility levels for the past 30 days are set at 8.08% for Epizyme Inc.. The simple moving average for the period of the last 20 days is -12.06% for EPZM stocks with a simple moving average of -60.34% for the last 200 days.

Analysts’ Opinion of EPZM

Many brokerage firms have already submitted their reports for EPZM stocks, with SVB Leerink repeating the rating for EPZM by listing it as a “Outperform.” The predicted price for EPZM in the upcoming period, according to SVB Leerink is $16 based on the research report published on May 07th of the previous year 2021.

Cowen, on the other hand, stated in their research note that they expect to see EPZM reach a price target of $14. The rating they have provided for EPZM stocks is “Outperform” according to the report published on April 23rd, 2021.

Credit Suisse gave a rating of “Outperform” to EPZM, setting the target price at $13 in the report published on March 31st of the previous year.

EPZM Trading at -30.16% from the 50-Day Moving Average

After a stumble in the market that brought EPZM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -81.01% of loss for the given period.

Volatility was left at 8.08%, however, over the last 30 days, the volatility rate increased by 8.64%, as shares sank -13.00% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -45.96% lower at present.

During the last 5 trading sessions, EPZM fell by -10.07%, which changed the moving average for the period of 200-days by -69.46% in comparison to the 20-day moving average, which settled at $2.72. In addition, Epizyme Inc. saw -3.60% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at EPZM starting from Agarwal Shefali, who sale 1,780 shares at the price of $2.93 back on Dec 06. After this action, Agarwal Shefali now owns 163,004 shares of Epizyme Inc., valued at $5,215 using the latest closing price.

Kutok Jeffery, the Chief Scientific Officer of Epizyme Inc., sale 2,029 shares at $8.80 during a trade that took place back on Apr 05, which means that Kutok Jeffery is holding 54,028 shares at $17,855 based on the most recent closing price.

Stock Fundamentals for EPZM

Current profitability levels for the company are sitting at:

  • -1430.12 for the present operating margin
  • +42.56 for the gross margin

The net margin for Epizyme Inc. stands at -1469.95. The total capital return value is set at -54.70, while invested capital returns managed to touch -56.75. Equity return is now at value -432.90, with -68.20 for asset returns.

Based on Epizyme Inc. (EPZM), the company’s capital structure generated 135.17 points at debt to equity in total, while total debt to capital is 57.48. Total debt to assets is 52.25, with long-term debt to equity ratio resting at 164.86. Finally, the long-term debt to capital ratio is 56.40.

>> 7 Top Picks for the Post-Pandemic Economy <<

When we switch over and look at the enterprise to sales, we see a ratio of 3.22, with the company’s debt to enterprise value settled at 0.25. The receivables turnover for the company is 4.51 and the total asset turnover is 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.33.

Leave a Comment

Your email address will not be published.

A Lesson to Learn: Ovintiv Inc. (OVV)

Ovintiv Inc. (NYSE:OVV) went up by 3.73% from its latest closing price compared to the recent 1-year high of $41.33. The company’s stock price has




Download Free eBook For


100% free. stop anytime no spam